NF-κB associated markers of prognosis in early and metastatic triple negative breast cancer
Payton De La Cruz(Providence College), Nicole E. James(Royal Berkshire Hospital), M. Aquino(Brown University), Christoph Schorl(Brown University), Andrew Elliott(Caris Life Sciences (United States)), Julia McAdams(Women & Infants Hospital of Rhode Island), Aileen I. Fernandez(Yale University), Maryam B. Lustberg(Yale Cancer Center), Jennifer R. Ribeiro(Women & Infants Hospital of Rhode Island)
Cited by 11
Related Papers
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
|JAMA Oncology|2022|347
Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer
|Modern Pathology|2021|166
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
|Laboratory Investigation|2022|141
The effect of using a large language model to respond to patient messages
|The Lancet Digital Health|2024|122
Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry
|Modern Pathology|2023|98